Technology area: Biotechnology & Pharmaceuticals
1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready
Viewpoint Molecular Targeting Inc. is currently navigating 2 pending office actions within the Biotechnology & Pharmaceuticals technology area. Both of these actions are assigned to 1 distinct examiner, MOSHER, ERIC PARKER. The portfolio is further concentrated within 1 distinct art unit, which suggests that the company's current patenting efforts are focused on a very specific biotechnological application. This centralization can simplify the management of intellectual property assets.
MOSHER, ERIC PARKER acts as the busiest examiner for the company, holding 2 busiest examiner pending actions. Because 1 distinct examiner is responsible for all pending matters, the company faces a consistent examination style across its active applications. This allows for a more predictable prosecution timeline and strategy. The presence of 2 pending office actions indicates a moderate level of activity within this specific technical domain.
The fact that the company operates within 1 distinct art unit implies that the legal team can specialize in the nuances of that specific unit's practices. With 2 pending office actions, the workload is manageable but requires coordinated responses to the same examiner. Practitioners can leverage the feedback from one action to inform the strategy for the other. This focused approach is typical for companies developing specialized molecular targeting technologies.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Double-patenting + other | 1 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSHER, ERIC PARKER | 1 | 100.0% | +0.0% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18767232 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | MOSHER, ERIC PARKER | — |
| Art Unit | Apps |
|---|---|
| 1612 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18767232 | FIBROBLAST ACTIVATION PROTEIN TARGETING PEPTIDES | MOSHER, ERIC PARKER | 1612 | §112DP | Non-Final OA | — | Pending | Jul 09, 2024 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialViewpoint Molecular Targeting Inc. has 1 pending office actions as of October 2026, spread across 1 art units and 1 examiners.
Eric Parker Mosher has the most, with 1 of Viewpoint Molecular Targeting Inc.'s pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
